NK012 is a 'nanodevice' formulation of SN-38 (an irinotecan metabolite). NK012 is an SN-38-releasing polymeric micelle constructed by covalently attaching SN-38 to the block copolymer PEG-PGlu, followed by self-assembly of amphiphilic block copolymers in aqueous media.
It has entered phase II clinical trials for triple-negative breast cancer and relapsed small cell lung cancer.
References
NK012 Wikipedia(Text) CC BY-SA